IMVT

Immunovant (IMVT)

About Immunovant (IMVT)

Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.

Details

Daily high

$26.27

Daily low

$25.25

Price at open

$25.44

52 Week High

$45.58

52 Week Low

$24.61

Market cap

3.8B

Dividend yield

0.00%

Volume

3.2M

Avg. volume

974,623

P/E ratio

-11.67

Immunovant News